Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

health sharing group pty ltd - evening primrose oil -

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - hyaluronidase, quantity: 1500 iu - injection, powder for - excipient ingredients: sodium hydroxide - hypodermoclysis. obstetrics anaesthesia. prevention of postpartum haemorrhage (with ergometrine). as an aid to local anaesthesia in ophthalmology. as an aid to local anaesthesia in fracture reduction. subcutaneous administration of radiopaque substances in pyelography.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - folic acid, quantity: 0.35 mg; ferrous fumarate, quantity: 310 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; povidone; titanium dioxide; iron oxide red; microcrystalline cellulose; purified talc; sodium starch glycollate type a; hypromellose; magnesium stearate; triethyl citrate - to be given as a source of iron and folic acid for the prevention and treatment of iron and folic acid deficiency anaemias. it may also be used for the prevention and treatment of these conditions during pregnancy.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - ferrous fumarate, quantity: 200 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; iron oxide yellow; triethyl citrate; iron oxide red; magnesium stearate; povidone; hypromellose; purified talc; titanium dioxide; microcrystalline cellulose; iron oxide black - source of iron for the treatment and prevention of iron deficiency and iron deficiency anaemia.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - loperamide hydrochloride, quantity: 2 mg - capsule, hard - excipient ingredients: patent blue v; purified talc; sunset yellow fcf; magnesium stearate; carmoisine; quinoline yellow; sodium lauryl sulfate; titanium dioxide; maize starch; lactose monohydrate; gelatin - control and symptomatic treatment of acute non-specific diarrhoea.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

trans-pacific healthcare australia pty ltd -

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amitriptyline hydrochloride, quantity: 50 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; croscarmellose sodium; colloidal anhydrous silica; purified talc; magnesium stearate; macrogol 6000; hypromellose; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - for the treatment of major depression. entrip 50mg tablets are indicated only for the maintenance treatment of major depression (see precautions). nocturnal enuresis where organic pathology has been excluded.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amitriptyline hydrochloride, quantity: 25 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; croscarmellose sodium; colloidal anhydrous silica; purified talc; magnesium stearate; macrogol 6000; hypromellose; titanium dioxide; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - for the treatment of major depression. nocturnal enuresis where organic pathology has been excluded.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amitriptyline hydrochloride, quantity: 10 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; croscarmellose sodium; colloidal anhydrous silica; purified talc; magnesium stearate; macrogol 6000; hypromellose; titanium dioxide; brilliant blue fcf aluminium lake; polyvinyl alcohol; macrogol 3350 - for the treatment of major depression. nocturnal enuresis where organic pathology has been excluded.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine juno is indicated for the treatment of patients with intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), chronic myelomonocytic leukemia (cmmol (10-29 percent marrow blasts without myeloproliferative disorder)), acute myeloid leukemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who), in whom allogenic stem cell transplantation is not indicated.